Jim Simons Tenaya Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$62.3 Billion
Q1 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Tenaya Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,541,725 shares of TNYA stock, worth $740,028. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,541,725

Holding current value

$740,028

% of portfolio

0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$0.44 - $1.52 $678,359 - $2.34 Million	1,541,725 New	1,541,725 $878,000
Q3 2024 Nov 13, 2024	BUY	$1.93 - $3.99 $430,405 - $889,801	223,008 Added 141.63%	380,468 $734,000
Q2 2024 Aug 09, 2024	BUY	$2.72 - $4.99 $252,851 - $463,870	92,960 Added 144.12%	157,460 $488,000
Q1 2024 May 13, 2024	SELL	$2.88 - $6.8 $1.2 Million - $2.84 Million	-417,825 Reduced 86.63%	64,500 $337,000
Q4 2023 Feb 13, 2024	BUY	$1.73 - $3.39 $84,294 - $165,177	48,725 Added 11.24%	482,325 $1.56 Million
Q3 2023 Nov 14, 2023	BUY	$2.55 - $5.65 $866,489 - $1.92 Million	339,800 Added 362.26%	433,600 $1.11 Million
Q2 2023 Aug 11, 2023	SELL	$2.64 - $7.64 $451,704 - $1.31 Million	-171,100 Reduced 64.59%	93,800 $551,000
Q1 2023 May 12, 2023	BUY	$1.92 - $3.59 $107,176 - $200,397	55,821 Added 26.7%	264,900 $755,000
Q4 2022 Feb 13, 2023	BUY	$1.68 - $3.19 $72,036 - $136,784	42,879 Added 25.8%	209,079 $420,000
Q3 2022 Nov 14, 2022	BUY	$2.9 - $5.88 $481,980 - $977,256	166,200 New	166,200 $482,000

Others Institutions Holding TNYA

# of Institutions

106

Shares Held

48.6M

Call Options Held

74.4K

Put Options Held

78.4K

View Full List

About Tenaya Therapeutics, Inc.

Ticker TNYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,364,700
Market Cap $19.9M
Description
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...

More about TNYA

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account